Watch IBIO. Know when insiders buy.
One email the day a filing lands. Free.
IBIO
iBio, Inc.
1.25
+0.07 +5.93%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · shorts 42
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $80.4MP/E —DIV YIELD —FCF YIELD -29.60%REV TTM $100K −75.0%NET INCOME −$33MNET CASH —52W 0.79 – 3.07SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | $0 | −100.0% | — | −$11.4M | −$10.6M | — | -0.07 | −$6.2M | $19K | −$6.2M | Aug 28 |
| Q3 2026 · Mar 31 | $0 | — | — | −$8.4M | −$7.7M | — | -0.06 | −$6.1M | $11K | −$6.1M | May 12 |
| Q2 2026 · Dec 31 | $0 | −100.0% | — | −$9.4M | −$9M | — | -0.09 | −$5.2M | $516K | −$5.8M | May 12 |
| Q1 2026 · Sep 30 | $100K | — | — | −$6M | −$5.7M | — | -0.11 | −$5.7M | $32K | −$5.7M | May 12 |
| Q4 2025 · Jun 30derived | $200K | +14.3% | — | −$5.2M | −$5.2M | — | -0.31 | −$4.6M | $1K | −$4.6M | Aug 28 |
| Q3 2025 · Mar 31 | $0 | — | — | −$4.9M | −$4.9M | — | -0.49 | −$3.1M | $14K | −$3.1M | May 12 |
| Q2 2025 · Dec 31 | $200K | — | — | −$4.4M | −$4.4M | — | -0.48 | −$3.9M | $1K | −$3.9M | May 12 |
| Q1 2025 · Sep 30 | $0 | −100.0% | — | −$4.1M | −$4M | — | -0.46 | −$3.7M | $0 | −$3.7M | May 12 |
| Q4 2024 · Jun 30derived | $175K | — | — | −$3.4M | −$7.8M | — | 1.12 | −$4.9M | $210K | −$5.1M | Sep 5 |
| Q3 2024 · Mar 31 | $0 | — | — | −$3.6M | −$3.2M | — | -0.85 | −$3.7M | $0 | −$3.7M | May 2 |
| Q2 2024 · Dec 31 | $0 | — | — | −$4.5M | −$8.2M | — | -4.42 | −$4.7M | — | — | May 2 |
| Q1 2024 · Sep 30 | $50K | — | — | −$5.1M | −$5.7M | — | -4.80 | −$5.3M | — | — | May 2 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | $100K | — | −$35.1M | −$33M | -33044.0% | -0.32 | −$23.2M | $578K | −$23.8M | — | — |
| FY2025 · to Jun 30 | $400K | — | −$18.6M | −$18.4M | -4594.3% | -1.75 | −$15.3M | $16K | −$15.3M | — | — |
| FY2024 · to Jun 30 | $225K | — | −$16.6M | −$24.9M | -11069.8% | -6.50 | −$18.6M | $210K | −$18.8M | — | — |
| FY2023 · to Jun 30 | $0 | — | −$29.3M | −$65M | — | -106.19 | −$30.4M | $5.7M | −$36.2M | — | — |
| FY2022 · to Jun 30 | $1.9M | 115.0% | −$29.7M | −$50.3M | -2670.0% | -5.78 | −$37.5M | $7.3M | −$44.8M | — | — |
| FY2021 · to Jun 30 | $2.4M | 38.3% | −$31.1M | −$23.2M | -978.8% | -3.00 | −$30.1M | $4.9M | −$35M | — | — |
Every number comes from iBio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.